Contract development and manufacturing company ProBioGen and Canadian antibody therapeutics company Zymeworks have signed an agreement where ProBioGen will complete cell line development of a Zymeworks candidate.
ProBioGen will apply its GlymaxX Technology to enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
Volker Sandig, chief scientific officer of ProBioGen , said: “We have been working productively with Zymeworks for some time already and look forward to contributing to the success of Zymeworks’ Azymetric bi-specific antibody platform. Our proprietary CHO expression platform is ideally suited for the expression of bi-specific antibodies with high purities and expression titers. The implementation of our innovative GlymaxX technology for enhanced cancer cell killing underlines the flexibility of our expression platforms’ tool box approach.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze